Galantamine‐ER For Cognitive Dysfunction In Bipolar Disorder and Correlation with Hippocampal Neuronal Viability: A Proof‐of‐Concept Study

Iosifescu, Dan V.; Moore, Constance M.; Deckersbach, Thilo; Tilley, Claire A.; Ostacher, Michael J.; Sachs, Gary S.; Nierenberg, Andrew A.

doi:10.1111/j.1755-5949.2009.00090.x

Cited by 45 publications

(48 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Quality assessed with the Jadad scale ( Table 1; eTable 1) indicated that 4 studies Keck et al, 2009;Kelly, 2008b;Schrauwen and Ghaemi, 2006) had no quality (Jadad's scale=0), 4 (Gildengers et al, 2008;Iosifescu et al, 2009;Keck et al, 2009;Koukopoulos et al, 2012) had low quality (Jadad's scale=1), 1 (Iosifescu et al, 2009) had medium quality (Jadad's scale=2), and 5 (Ae et al, 2006;Anand et al, 2012;Ghaemi et al, 2009;Lee et al, 2014) were of high quality (Jadad's scale>3). All the studies with high quality were also RCTs, while among the studies with other designs, only 1 (Iosifescu et al, 2009) included a control group, reaching a medium quality.…”

Section: Methodological Quality Of Included Studiesmentioning

confidence: 99%

“…All the studies with high quality were also RCTs, while among the studies with other designs, only 1 (Iosifescu et al, 2009) included a control group, reaching a medium quality.…”

Section: Methodological Quality Of Included Studiesmentioning

confidence: 99%

“…All studies focused on the short-or medium-term treatment and none reported results on relapse prevention. Nine studies were conducted in the USA (Ae et al, 2006;Anand et al, 2012;Burt et al, 1999;Ghaemi et al, 2009;Gildengers et al, 2008;Iosifescu et al, 2009;Keck et al, 2009;Kelly, 2008a;Schrauwen and Ghaemi, 2006), 2 in Asia Lee et al, 2014) and one in Europe (Koukopoulos et al, 2012). Five studies were RCTs, 2 naturalistic case series, 2 retrospective case series, 2 open label trials without a control group and 1 with a control group.…”

Section: Study and Patient Characteristicsmentioning

confidence: 99%

“…Three studies (Ghaemi et al, 2009;Iosifescu et al, 2009;Schrauwen and Ghaemi, 2006) explored the effect of galantamine (treated=21; controls: 20, 10 placebo and 10 healthy subjects), one was a RCT (Ghaemi et al, 2009). Four studies (Anand et al, 2012;Keck et al, 2009;Koukopoulos et al, 2012;Lee et al, 2014) investigated the use of memantine (treated=152; controls=88, all placebo) with 2 studies (Anand et al, 2012;Lee et al, 2014) with a RCT design.…”

Section: Study and Patient Characteristicsmentioning

confidence: 99%

“…The 12 included studies (Ae et al, 2006;Anand et al, 2012;Burt et al, 1999;Chen et al, 2013;Ghaemi et al, 2009;Gildengers et al, 2008;Iosifescu et al, 2009;Keck et al, 2009;Koukopoulos et al, 2012;Lee et al, 2014;Schrauwen and Ghaemi, 2006) included a total of 434 participants (treated=275, controls=147) for an average follow-up period of 20 weeks. All studies focused on the short-or medium-term treatment and none reported results on relapse prevention.…”

Section: Study and Patient Characteristicsmentioning

confidence: 99%

See 4 more Smart Citations

Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions

Veronese

Solmi

Luchini

et al. 2016

Journal of Affective Disorders

View full text Add to dashboard Cite

show abstract

Section: Methodological Quality Of Included Studiesmentioning

confidence: 99%

“…All the studies with high quality were also RCTs, while among the studies with other designs, only 1 (Iosifescu et al, 2009) included a control group, reaching a medium quality.…”

Section: Methodological Quality Of Included Studiesmentioning

confidence: 99%

Section: Study and Patient Characteristicsmentioning

confidence: 99%

Section: Study and Patient Characteristicsmentioning

confidence: 99%

Section: Study and Patient Characteristicsmentioning

confidence: 99%

See 3 more Smart Citations

Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions

Veronese

Solmi

Luchini

et al. 2016

Journal of Affective Disorders

View full text Add to dashboard Cite

show abstract

Clinical Trials that Utilize MRS as a Biomarker

Lin

Rowland

Griffiths

2016

eMagRes

View full text Add to dashboard Cite

Magnetic resonance spectroscopy (MRS) is an ideal tool for therapeutic monitoring in clinical trials although its role has not been formally examined. An initial search for the use of MRS in a clinical trials database showed 488 studies; however, many are ongoing and limited information is available about them. Therefore, the results were cross-referenced with the scientific literature to find those studies that have been completed and have produced peer-reviewed publications. This yielded 61 studies, demonstrating that MRS is actively used in clinical trials. Its most frequent use is to study hepatic lipid content. This is followed by studies of skeletal muscle, using both proton and phosphorous MRS, and finally the brain, which surprisingly was the subject of only 15% of the total MRS studies found. A review and summary of these studies is provided to better understand how MRS is used in clinical trials, and to assess its importance as a noninvasive and quantitative biomarker for disease.

show abstract

Alpha7 nicotinic‐N‐methyl‐D‐aspartate hypothesis in the treatment of schizophrenia and beyond

Koola

2020

Human Psychopharmacology

View full text Add to dashboard Cite

Development of novel treatments for positive, cognitive, and negative symptoms continue to be a high‐priority area of schizophrenia research and a major unmet clinical need. Given that all randomized controlled trials (RCTs) conducted to date failed with one add‐on medication/mechanism of action, future RCTs with the same approach are not warranted. Even if the field develops a medication for cognition, others are still needed to treat negative and positive symptoms. Therefore, fixing one domain does not completely solve the problem. Also, targeting the cholinergic system, glutamatergic system, and cholinergic plus alpha7 nicotinic and N‐methyl‐D‐aspartate (NMDA) receptors failed independently. Hence, targeting other less important pathophysiological mechanisms/targets is unlikely to be successful. Meta‐analyses of RCTs targeting major pathophysiological mechanisms have found some efficacy signal in schizophrenia; thus, combination treatments with different mechanisms of action may enhance the efficacy signal. The objective of this article is to highlight the importance of conducting RCTs with novel combination treatments in schizophrenia to develop antischizophrenia treatments. Positive RCTs with novel combination treatments that target the alpha7 nicotinic and NMDA receptors simultaneously may lead to a disease‐modifying therapeutic armamentarium in schizophrenia. Novel combination treatments that concurrently improve the three domains of psychopathology and several prognostic and theranostic biomarkers may facilitate therapeutic discovery in schizophrenia.

show abstract

Galantamine‐ER For Cognitive Dysfunction In Bipolar Disorder and Correlation with Hippocampal Neuronal Viability: A Proof‐of‐Concept Study

Abstract: Bipolar subjects had cognitive dysfunction; treatment with Galantamine-ER was associated with improved cognition and with increases in neuronal viability and normalization of lipid membrane metabolism in the left hippocampus. This study was registered on ClinicalTrials.gov (NCT00181636).

Cited by 45 publications

References 66 publications

Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions

Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions

Clinical Trials that Utilize MRS as a Biomarker

Alpha7 nicotinic‐N‐methyl‐D‐aspartate hypothesis in the treatment of schizophrenia and beyond

Contact Info

Product

Resources

About